The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism

NCT00259727 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2009-09-30

No results posted yet for this study

Summary

The purpose of this study is to determine the mechanisms by which HIV protease inhibitors contribute to the development of diabetes in HIV-infected patients. The investigators propose that some HIV protease inhibitors impair insulin secretion and increase the production of glucose by the liver.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Grace Lee, MD · VA Medical Center, San Francisco

Eligibility

Min Age
18 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00259727 on ClinicalTrials.gov